OBJECTIVE: To compare the effects of arginine-vasopressin (AVP) and norepinephrine (NE) on hemodynamic variables, organ dysfunction, and adverse events in early hyperdynamic septic shock. DESIGN AND SETTING: Randomized, controlled, open-label trial. PATIENTS AND PARTICIPANTS: Twenty-three patients with early (12h) hyperdynamic septic shock in two teaching hospitals. INTERVENTIONS: AVP (0.04-0.20 Umin(-1), n=13) as a single agent or NE (0.1-2.8microg kg(-1)min(-1), n=10) infusion for 48[Symbol: see text]h to achieve mean arterial pressure at or above 70mmHg. MEASUREMENTS AND RESULTS:Hemodynamic parameters and Sequential Organ Failure Assessment (SOFA) score were measured. AVP and NE equally increased mean arterial pressure over 48h, but NE was required in 36% of AVP patients at 48h. Compared to baseline, AVP increased systemic vascular resistance, decreased exposure to NE, decreased cardiac output by decreasing heart rate, increased creatinine clearance, and improved SOFA score. The PrCO(2) - PaCO(2) difference remained stable throughout the study. One AVP patient developed acute coronary syndrome with dose-dependent ECG changes. Three patients in both groups died during their ICU stay. CONCLUSION: In early hyperdynamic septic shock, the administration of high-dose AVP as a single agent fails to increase mean arterial pressure in the first hour but maintains it above 70mmHg in two-thirds of patients at 48h. AVP decreases NE exposure, has no effect on the PrCO(2) - PaCO(2 )difference, and improves renal function and SOFA score.
RCT Entities:
OBJECTIVE: To compare the effects of arginine-vasopressin (AVP) and norepinephrine (NE) on hemodynamic variables, organ dysfunction, and adverse events in early hyperdynamic septic shock. DESIGN AND SETTING: Randomized, controlled, open-label trial. PATIENTS AND PARTICIPANTS: Twenty-three patients with early (12h) hyperdynamic septic shock in two teaching hospitals. INTERVENTIONS:AVP (0.04-0.20 Umin(-1), n=13) as a single agent or NE (0.1-2.8microg kg(-1)min(-1), n=10) infusion for 48[Symbol: see text]h to achieve mean arterial pressure at or above 70mmHg. MEASUREMENTS AND RESULTS: Hemodynamic parameters and Sequential Organ Failure Assessment (SOFA) score were measured. AVP and NE equally increased mean arterial pressure over 48h, but NE was required in 36% of AVPpatients at 48h. Compared to baseline, AVP increased systemic vascular resistance, decreased exposure to NE, decreased cardiac output by decreasing heart rate, increased creatinine clearance, and improved SOFA score. The PrCO(2) - PaCO(2) difference remained stable throughout the study. One AVPpatient developed acute coronary syndrome with dose-dependent ECG changes. Three patients in both groups died during their ICU stay. CONCLUSION: In early hyperdynamic septic shock, the administration of high-dose AVP as a single agent fails to increase mean arterial pressure in the first hour but maintains it above 70mmHg in two-thirds of patients at 48h. AVP decreases NE exposure, has no effect on the PrCO(2) - PaCO(2 )difference, and improves renal function and SOFA score.
Authors: Günter Luckner; Martin W Dünser; Stefan Jochberger; Viktoria D Mayr; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Andreas J Mayr; Barbara Friesenecker Journal: Crit Care Med Date: 2005-11 Impact factor: 7.598
Authors: Mitchell M Levy; William L Macias; Jean-Louis Vincent; James A Russell; Eliezer Silva; Benjamin Trzaskoma; Mark D Williams Journal: Crit Care Med Date: 2005-10 Impact factor: 7.598
Authors: Stefan Jochberger; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Barbara Friesenecker; Andreas J Mayr; Martin W Dünser Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: R Moreno; J L Vincent; R Matos; A Mendonça; F Cantraine; L Thijs; J Takala; C Sprung; M Antonelli; H Bruining; S Willatts Journal: Intensive Care Med Date: 1999-07 Impact factor: 17.440
Authors: Pierre Asfar; Marc Pierrot; Nary Veal; Frédéric Moal; Frédéric Oberti; Vincent Croquet; Olivier Douay; Yves Gallois; Jean-Louis Saumet; Philippe Alquier; Paul Calès Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard Journal: Intensive Care Med Date: 2007-02-14 Impact factor: 17.440
Authors: Frederic Chagnon; Vishal S Vaidya; Gerard E Plante; Joseph V Bonventre; Alfred Bernard; Chantal Guindi; Olivier Lesur Journal: Crit Care Med Date: 2008-11 Impact factor: 7.598
Authors: Florian Simon; Ricardo Giudici; Angelika Scheuerle; Michael Gröger; Pierre Asfar; Josef A Vogt; Ulrich Wachter; Franz Ploner; Michael Georgieff; Peter Möller; Régent Laporte; Peter Radermacher; Enrico Calzia; Balázs Hauser Journal: Crit Care Date: 2009-07-10 Impact factor: 9.097
Authors: Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal Journal: Crit Care Date: 2009-08-10 Impact factor: 9.097